clorazepate dipotassium has been researched along with s 16924 in 1 studies
| Studies (clorazepate dipotassium) | Trials (clorazepate dipotassium) | Recent Studies (post-2010) (clorazepate dipotassium) | Studies (s 16924) | Trials (s 16924) | Recent Studies (post-2010) (s 16924) |
|---|---|---|---|---|---|
| 325 | 90 | 11 | 11 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brocco, M; Dekeyne, A; Gobert, A; Millan, MJ; Schreiber, R | 1 |
1 other study(ies) available for clorazepate dipotassium and s 16924
| Article | Year |
|---|---|
S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloper
Topics: Aggression; Animals; Antipsychotic Agents; Autoreceptors; Clorazepate Dipotassium; Clozapine; Columbidae; Conflict, Psychological; Haloperidol; Male; Maze Learning; Mice; Pyrrolidines; Rats; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Time Factors; Vocalization, Animal | 1999 |